Will my condition relapse after I stop taking Sotatercept-Winrevair?

Sotatercept-Winrevair is a new recombinant fusion protein targeting pulmonary arterial hypertension (PAH). It has a unique mechanism of action. It directly interferes with abnormal vascular remodeling and erythropoiesis by regulating bone morphogenetic protein (BMP) and TGF-β superfamily signaling pathways, thereby improving patients' hemodynamic indicators and hemoglobin levels. Its clinical value lies not only in short-term relief of symptoms, but also in fundamentally improving vascular and bone marrow functions by intervening in the basic pathological process of the disease.

However, Soltercept is not a curative drug. It mainly maintains therapeutic effects by continuously interfering with pathological signaling pathways. Clinical and overseas research data show that once the drug is discontinued, the patient's erythropoiesis and hemoglobin levels may gradually decrease, and the pathological progression of pulmonary hypertension may continue. This resurgence or "rebound" is not caused by drug toxicity, but the result of the patient's underlying disease itself not being cured. Particularly for patients who have long-term dependence on Soltercept to maintain hemoglobin levels or control pulmonary artery pressure, discontinuation of the drug may lead to worsening of symptoms, decrease in hemoglobin, or worsening of cardiorespiratory function within weeks to months.

Therefore, it is clinically recommended that sotercept should be discontinued under the guidance of a professional doctor, and an individualized follow-up and monitoring plan should be developed. Patients need to closely observe changes in hemoglobin levels, pulmonary artery pressure and symptoms during the discontinuation period. Once obvious anemia or dyspnea occurs, they should contact their doctor immediately to consider restarting treatment or adjusting other supportive therapies. Some studies have shown that progressive dose adjustment or transitional combination therapy after drug withdrawal can delay the decline in hemoglobin and recurrence of symptoms to a certain extent, but this requires strict individualized management.

Reference materials:https://www.drugs.com/mtm/sotatercept.html